JP2005505503A - Ｅ６及び／又はｅ７パピローマウイルスタンパク質に由来するペプチドの混合物並びにその使用 - Google Patents

Ｅ６及び／又はｅ７パピローマウイルスタンパク質に由来するペプチドの混合物並びにその使用 Download PDF

Info

Publication number
JP2005505503A
JP2005505503A JP2002587459A JP2002587459A JP2005505503A JP 2005505503 A JP2005505503 A JP 2005505503A JP 2002587459 A JP2002587459 A JP 2002587459A JP 2002587459 A JP2002587459 A JP 2002587459A JP 2005505503 A JP2005505503 A JP 2005505503A
Authority
JP
Japan
Prior art keywords
peptide
peptides
positions
protein
hpv16
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002587459A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005505503A5 (enExample
Inventor
マイレア，ベルナルド
ブールゴール−ヴィラダ，イサベル
ポウヴェレ−モラティレ，サンドラ
グイレット，ジャン−ジェラード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Original Assignee
Commissariat a lEnergie Atomique CEA
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat a lEnergie Atomique CEA, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Commissariat a lEnergie Atomique CEA
Publication of JP2005505503A publication Critical patent/JP2005505503A/ja
Publication of JP2005505503A5 publication Critical patent/JP2005505503A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
JP2002587459A 2001-05-04 2002-05-03 Ｅ６及び／又はｅ７パピローマウイルスタンパク質に由来するペプチドの混合物並びにその使用 Withdrawn JP2005505503A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0105980A FR2824326B1 (fr) 2001-05-04 2001-05-04 Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
PCT/FR2002/001533 WO2002090382A2 (fr) 2001-05-04 2002-05-03 Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications

Publications (2)

Publication Number Publication Date
JP2005505503A true JP2005505503A (ja) 2005-02-24
JP2005505503A5 JP2005505503A5 (enExample) 2005-12-22

Family

ID=8862980

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002587459A Withdrawn JP2005505503A (ja) 2001-05-04 2002-05-03 Ｅ６及び／又はｅ７パピローマウイルスタンパク質に由来するペプチドの混合物並びにその使用

Country Status (7)

Country Link
US (2) US7488791B2 (enExample)
EP (1) EP1383535A2 (enExample)
JP (1) JP2005505503A (enExample)
AU (1) AU2002302713A1 (enExample)
CA (1) CA2446062A1 (enExample)
FR (1) FR2824326B1 (enExample)
WO (1) WO2002090382A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021522239A (ja) * 2018-04-26 2021-08-30 アジェナス インコーポレイテッド 熱ショックタンパク質結合ペプチド組成物およびその使用方法
JP2022509221A (ja) * 2018-11-28 2022-01-20 ザ ジェネラル ホスピタル コーポレイション 共生ウイルスに対するｔ細胞指向性抗がんワクチン
JP2023512670A (ja) * 2020-02-10 2023-03-28 ザ・ジョンズ・ホプキンス・ユニバーシティ 同種異系、腫瘍特異的なｃｄ４＋ ｔ細胞の注射移植を用いたがん免疫療法
US12359167B2 (en) 2012-05-08 2025-07-15 The Johns Hopkins University Methods and compositions for infusion of transiently engrafting, selected populations of allogeneic lymphocytes to treat cancer

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
DE10336916B4 (de) * 2003-08-07 2015-02-19 Danfoss A/S Regelventil und Wärmetauscheranordnung
WO2006037059A2 (en) * 2004-09-27 2006-04-06 The Johns Hopkins Universtiy Point-of-care mass spectrometer system
JP2008044848A (ja) * 2004-11-30 2008-02-28 Univ Kurume Ｈｌａ−ａ２４拘束性腫瘍抗原ペプチド
US7972776B2 (en) * 2005-11-15 2011-07-05 Oncohealth Corporation Protein chips for HPV detection
ES2310072B1 (es) * 2005-12-23 2009-11-16 Proyecto De Biomedicina Cima, S.L. Nuevos peptidos determinantes antigenicos t colaboradores (/dth).
US8859218B2 (en) * 2008-06-13 2014-10-14 Oncohealth Corp. In situ detection of early stages and late stages HPV infection
US8968995B2 (en) * 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
AU2013205259B2 (en) * 2007-05-31 2015-06-11 Isa Pharmaceuticals B.V. HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
ES2496916T3 (es) 2007-05-31 2014-09-22 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Epítopo de HPV al que se dirigen células T que infiltran tumores malignos cervicales para su uso en vacunas
KR20090103571A (ko) * 2008-03-28 2009-10-01 바이오코아 주식회사 면역성 펩타이드 및 그 펩타이드를 포함하는 ｈｐｖ 관련질환 예방 또는 치료용 조성물
WO2009129227A1 (en) 2008-04-17 2009-10-22 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
EP2427763A4 (en) 2009-05-07 2013-08-21 Oncohealth Corp IDENTIFICATION OF HIGH GRADE OR CIN2 FOR DETECTION, MONITORING AND DIAGNOSIS, AT EARLY STAGES AND ADVANCED STAGES, OF HUMAN PAPILLOMAVIRUS (HPV) AND HPV ASSOCIATED CANCERS
AR074485A1 (es) * 2009-12-04 2011-01-19 Consejo Nac Invest Cient Tec Vacuna contra lesiones neoplasicas o cancerosas causadas por el virus del papiloma humano (vph), procedimientos, usos y metodos
EP2521914A4 (en) 2010-01-08 2013-07-10 Oncohealth Corp CELL-BASED HPV IMMUNOTESTS HAVE A HIGH PERFORMANCE FOR DIAGNOSIS AND SCANNING OF HPV ASSOCIATED CANCER
CN102060929A (zh) * 2010-06-07 2011-05-18 夏书奇 T细胞免疫平衡肽
CN103282375B (zh) 2010-12-02 2017-01-11 比奥诺尔免疫有限公司 肽支架设计
CN105163753B (zh) 2012-06-15 2018-12-21 Pds生物科技公司 阳离子脂质疫苗组合物和使用方法
EP2897639A4 (en) 2012-09-21 2016-05-04 Frank Bedu-Addo IMPROVED VACCINATE COMPOSITIONS AND METHODS OF USE
FR3008099B1 (fr) 2013-07-05 2020-08-07 Commissariat Energie Atomique Peptides immunogenes de l'antigene tumoral cycline b1
EP3058956A1 (en) 2015-02-23 2016-08-24 Institut Curie Combined vaccination/radioterapy for cancer treatment
CA3005251A1 (en) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
EA201990071A1 (ru) 2016-06-20 2019-06-28 АйЭсЭй ФАРМАСЬЮТИКАЛЗ Б.В. Композиция пептидной вакцины
EP3267119A1 (en) 2016-07-07 2018-01-10 E.ON Sverige AB Combined heating and cooling system
CN110035765B (zh) * 2016-10-05 2024-04-02 Pds生物科技公司 新型hpv16非hla限制性t细胞疫苗、组合物及其使用方法
WO2019145792A1 (en) * 2018-01-24 2019-08-01 The Council Of The Queensland Institute Of Medical Research Hpv immunotherapy
EP4281106A4 (en) * 2021-01-21 2024-12-25 The General Hospital Corporation T-CELL-TARGETED ANTICANCER VACCINES AGAINST COMMENSAL VIRUSES FOR THE TREATMENT OF MUCOSAIC CARCINOMAS
WO2024223299A2 (en) 2023-04-26 2024-10-31 Isa Pharmaceuticals B.V. Methods of treating cancer by administering immunogenic compositions and a pd-1 inhibitor
CN119569831A (zh) * 2024-12-13 2025-03-07 深圳锦时生物科技有限公司 一种活性多肽及在预防和/或治疗hpv中的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999034826A1 (en) * 1998-01-09 1999-07-15 Circassia Limited Methods and compositions for desensitisation
JP2000506125A (ja) * 1996-02-24 2000-05-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 免疫調節のための医薬組成物
WO2001016163A2 (en) * 1999-08-27 2001-03-08 Eurodiagnostica Ab Peptide mixture and vaccine against a chronic viral infection
WO2001019408A1 (en) * 1999-09-16 2001-03-22 Zycos Inc. Nucleic acids encoding polyepitope polypeptides
WO2001021189A1 (en) * 1999-07-19 2001-03-29 Epimmune Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
WO2001024810A1 (en) * 1999-10-05 2001-04-12 Epimmune Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9001705D0 (sv) * 1990-05-11 1990-05-11 Medscand Ab Saett foer diagnostik av virusbaerande tumoerer genom immunoassay
US5932412A (en) * 1990-05-11 1999-08-03 Euro-Diagnostica Ab Synthetic peptides in human papillomaviruses 1, 5, 6, 8, 11, 16, 18, 31, 33 and 56, useful in immunoassay for diagnostic purposes
PT523391E (pt) * 1991-07-13 2003-08-29 Dade Behring Marburg Gmbh Utilizacao dos peptidos derivados dos genes hpv-16 e6 e e7 para fins de diagnostico
FR2794370B1 (fr) * 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000506125A (ja) * 1996-02-24 2000-05-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 免疫調節のための医薬組成物
WO1999034826A1 (en) * 1998-01-09 1999-07-15 Circassia Limited Methods and compositions for desensitisation
WO2001021189A1 (en) * 1999-07-19 2001-03-29 Epimmune Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
WO2001016163A2 (en) * 1999-08-27 2001-03-08 Eurodiagnostica Ab Peptide mixture and vaccine against a chronic viral infection
WO2001019408A1 (en) * 1999-09-16 2001-03-22 Zycos Inc. Nucleic acids encoding polyepitope polypeptides
WO2001024810A1 (en) * 1999-10-05 2001-04-12 Epimmune Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12359167B2 (en) 2012-05-08 2025-07-15 The Johns Hopkins University Methods and compositions for infusion of transiently engrafting, selected populations of allogeneic lymphocytes to treat cancer
JP2021522239A (ja) * 2018-04-26 2021-08-30 アジェナス インコーポレイテッド 熱ショックタンパク質結合ペプチド組成物およびその使用方法
JP2022509221A (ja) * 2018-11-28 2022-01-20 ザ ジェネラル ホスピタル コーポレイション 共生ウイルスに対するｔ細胞指向性抗がんワクチン
JP2025060647A (ja) * 2018-11-28 2025-04-10 ザ ジェネラル ホスピタル コーポレイション 共生ウイルスに対するｔ細胞指向性抗がんワクチン
JP7688576B2 (ja) 2018-11-28 2025-06-04 ザ ジェネラル ホスピタル コーポレイション 共生ウイルスに対するｔ細胞指向性抗がんワクチン
JP7688576B6 (ja) 2018-11-28 2025-07-04 ザ ジェネラル ホスピタル コーポレイション 共生ウイルスに対するｔ細胞指向性抗がんワクチン
JP2023512670A (ja) * 2020-02-10 2023-03-28 ザ・ジョンズ・ホプキンス・ユニバーシティ 同種異系、腫瘍特異的なｃｄ４＋ ｔ細胞の注射移植を用いたがん免疫療法

Also Published As

Publication number Publication date
EP1383535A2 (fr) 2004-01-28
AU2002302713A1 (en) 2002-11-18
US20100203080A1 (en) 2010-08-12
FR2824326B1 (fr) 2004-03-19
WO2002090382A3 (fr) 2003-10-02
CA2446062A1 (fr) 2002-11-14
US7488791B2 (en) 2009-02-10
FR2824326A1 (fr) 2002-11-08
US20040170644A1 (en) 2004-09-02
WO2002090382A2 (fr) 2002-11-14

Similar Documents

Publication Publication Date Title
US7488791B2 (en) Mixture of peptides derived from E6 and/or E7 papillomavirus proteins and uses thereof
US20230256075A1 (en) Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines
Davidson et al. Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7)
Baldwin et al. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia
US9115185B2 (en) Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
US8252893B2 (en) CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof
Zhao et al. A safe and potentiated multi-type HPV L2-E7 nanoparticle vaccine with combined prophylactic and therapeutic activity
Smith et al. Epitope specificity and longevity of a vaccine-induced human T cell response against HPV18
EP1288292A1 (en) Long peptides of 22-40 amino acid residues that induce and/or enhance antigen specific immune responses.
Lehtinen et al. Efficacy of preventive human papillomavirus vaccination
AU2015213420B2 (en) HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
EP1213299A1 (en) Immunogenic epitopes of human papilloma virus and uses thereof
AU2013205259B2 (en) HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
HK40019593A (en) Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050426

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080430

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080708

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100430

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100531

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20100716

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20130109